Cardiometabolic research (hypertension, dyslipidemia, cardiovascular diseases): Investigated for effects on blood pressure regulation, lipid metabolism, cholesterol control, and prevention of major adverse cardiovascular events in patients with diabetes and obesity
However, once opened, consistent refrigeration is essential
Wegovy is indicated for people ages 12 years and older who have: A BMI of 30 kg/m 2 or higher A BMI of 27 kg/m 2 to 29.9 kg/m 2 and at least one weight-related comorbidity , such as high blood pressure, type 2 diabetes, or obstructive sleep apnea Wegovy is also indicated to reduce the risk of major cardiovascular events , such as heart attack or stroke, in people who have obesity or overweight
Wegovy injection is approved to help adults and children aged 12 years and older with obesity or some adults with excess weight (overweight), who also have weight-related medical problems, to lose weight and keep the weight off, in addition to diet and exercise
It may relate to blood sugar fluctuations or reduced caloric intake
